A pilot observational study reported rare IRF7 variants appearing exclusively among fully vaccinated patients who developed severe or critical COVID-19. In the small cohort, 9 of 13 severe/critical vaccinated patients carried at least one IRF7 variant. The study frames a focused immunogenetic hypothesis around type I interferon regulation—genes that can influence antiviral control even when vaccination is in place. While the sample size limits definitive conclusions, it adds a concrete target pathway for follow-on validation in larger host-genetics cohorts. For biotech and translational groups, it reinforces that precision approaches to severe infection risk may extend beyond antibody titers to host interferon pathway genetics.